HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for AnaptysBio (NASDAQ:ANAB) and maintained a price target of $55.
October 31, 2024 | 9:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for AnaptysBio, maintaining a price target of $55, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $55 price target by a reputable analyst suggests a positive outlook for AnaptysBio. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100